Rosebank Industries slipped to a 330p share price this year, barely above the 330p equity issue that funded two acquisitions last month. The group now operates three businesses after spending $3.1bn (£2.3bn) on MW Components and CPM, and earlier buying Electrical Components International.

Simon Peckham, the chief executive, purchased £350,000 of shares on 26 June, while COO Liam Butterworth added £100,000. This buying activity signals confidence as the firm seeks to trim costs, close offices and shift the product mix toward higher‑margin aerospace work.

Berenberg Bank analysts label the share price dip an opportunistic entry point. They model a limited effect from a 50‑basis‑point rise in U.S. rates and note that Rosebank trades on 17 times forward consensus earnings for FY2027, with the mean target price 35 % above the current level.

Celia Baxter, a non‑executive director of Genus PLC, snapped up £50,000 of shares in the animal‑genetics group. Genus has outperformed the FTSE All‑Share by 46 % last year, driven by a 57 % jump in pre‑tax profit to £55.7mn and 53 % growth in EPS to 60.8p. A Chinese joint venture unlocked $160mn (£125mn) in cash, and the firm secured Canadian approval for a PRRS‑resistant pig gene edit. Investors will test the trajectory again when Genus reports full‑year results in early September.

The combination of a depressed share price, management alignment, and aggressive acquisition strategy creates a window for investors, but execution risk and potential güç of higher rates remain significant concerns.